Trademark: 88049205
Word
ACTIMED THERAPEUTICS
Status
Registered
Status Code
700
Status Date
Tuesday, May 24, 2022
Serial Number
88049205
Registration Number
6734037
Registration Date
Tuesday, May 24, 2022
Mark Type
4000
Filing Date
Monday, July 23, 2018
Published for Opposition
Tuesday, March 8, 2022

Trademark Owner History
Actimed Therapeutics Limited - Original Registrant

Classifications
5 Pharmaceutical, medical and therapeutic substances and preparations; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of cancers, and of severe or chronic illnesses and diseases; pharmaceutical, medical and therapeutic substances and preparations for treatment and management of physical function; pharmaceutical, medical and therapeutic substances and preparations for treatment and prevention of muscle wasting; pharmaceutical, medical and therapeutic substances and preparations for treatment and management of patient tolerance of therapies, in particular anticancer therapy; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of cachexia, in particular cancer cachexia; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of the side effects of medical treatments, in particular of cancer treatments; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the lung; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the kidney; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the heart; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the liver; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the brain; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic heart failure; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic renal failure; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic liver failure; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic obstructive pulmonary disease; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of neurological-muscular disorders
44 Information, advisory and consultancy services relating to medicine and healthcare; medical and surgical diagnosis and treatment services; medical analysis and reporting services relating to the treatment of patients; assessment and monitoring of patients; preparation of data and reports relating to medicine and healthcare; medical testing services relating to the diagnosis and treatment of illnesses, diseases and medical conditions; providing information relating to the management, preparation and dispensing of medications; medical, health, dentistry, veterinary and pharmaceutical services; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to severe or chronic illnesses and diseases; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of cancers, and of severe or chronic illnesses and diseases; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to physical function and muscle wasting; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to patient tolerance of therapies, in particular anticancer therapy; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of cachexia, in particular cancer cachexia; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of the side effects of medical treatments, in particular of cancer treatments; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the lung; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the kidney; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the heart; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the liver; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the brain; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic heart failure; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic renal failure; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic liver failure; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic obstructive pulmonary disease; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of neurological-muscular disorders; advisory, information and consultancy services relating to all the aforesaid services
"THERAPEUTICS"

Trademark Events
May 24, 2022
Notice Of Registration Confirmation Emailed
May 24, 2022
Registered-Principal Register
Mar 8, 2022
Official Gazette Publication Confirmation E-Mailed
Mar 8, 2022
Published For Opposition
Feb 16, 2022
Notification Of Notice Of Publication E-Mailed
Jan 27, 2022
Approved For Pub - Principal Register
Jan 27, 2022
Examiner's Amendment Entered
Jan 27, 2022
Notification Of Examiners Amendment E-Mailed
Jan 27, 2022
Examiners Amendment E-Mailed
Jan 27, 2022
Examiners Amendment -Written
Dec 16, 2021
Teas/Email Correspondence Entered
Dec 16, 2021
Correspondence Received In Law Office
Dec 9, 2021
Teas Response To Suspension Inquiry Received
Oct 1, 2021
Notification Of Inquiry As To Suspension E-Mailed
Oct 1, 2021
Inquiry To Suspension E-Mailed
Oct 1, 2021
Suspension Inquiry Written
Sep 24, 2021
Suspension Checked ¿ To Attorney For Action
Mar 2, 2021
Report Completed Suspension Check Case Still Suspended
Aug 6, 2020
Notification Of Letter Of Suspension E-Mailed
Aug 6, 2020
Letter Of Suspension E-Mailed
Aug 6, 2020
Suspension Letter Written
Jul 17, 2020
Teas/Email Correspondence Entered
Jul 17, 2020
Correspondence Received In Law Office
Jul 12, 2020
Assigned To Lie
Jun 30, 2020
Teas Response To Suspension Inquiry Received
Jan 27, 2020
Notification Of Inquiry As To Suspension E-Mailed
Jan 27, 2020
Inquiry To Suspension E-Mailed
Jan 27, 2020
Suspension Inquiry Written
Jul 2, 2019
Notification Of Letter Of Suspension E-Mailed
Jul 2, 2019
Letter Of Suspension E-Mailed
Jul 2, 2019
Suspension Letter Written
May 29, 2019
Teas/Email Correspondence Entered
May 28, 2019
Correspondence Received In Law Office
May 28, 2019
Teas Response To Office Action Received
Nov 27, 2018
Notification Of Non-Final Action E-Mailed
Nov 27, 2018
Non-Final Action E-Mailed
Nov 27, 2018
Non-Final Action Written
Nov 19, 2018
Assigned To Examiner
Nov 19, 2018
Assigned To Examiner
Nov 8, 2018
Assigned To Examiner
Jul 27, 2018
New Application Office Supplied Data Entered In Tram
Jul 26, 2018
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24